After your screening strategy is complete you will have one optimal formulation (it does not matter at this point what the buffer is). Your formulation will not completely eliminate aggregation, there will be some small level (typically <5%). After further evaluation you suspect that your mAb undergos reversible concentration dependent self-association (RCDSA). What is this type of aggregation? What are some impacts of RCDSA that make it a concern for a biopharmaceutical product? How will you confirm RCDSA is a mechanism of aggregation? What technique(s) will you use to evaluate this phenomena, describe in detail how the technique can inform you.